The identification of at-risk individuals prior to transplantation may enable implementation of measures to prevent
or delay PTDM development, while early detection facilitates prompt management and may prevent acute and
chronic complications. Thus, in this review, we examine proposed tools for the prediction of PTDM for use prior to and
following solid organ transplantation. This includes PTDM prediction models based on biochemical assessments of glycaemia
and other indices, in addition to those solely based on clinical parameters. We also examine the available methods
for diagnosis of PTDM early and late post-transplant, including the advantages and limitations of fasting plasma glucose
(FPG), OGTT, random plasma glucose and HbA1c assessment. Key findings are that OGTT should remain the gold standard
diagnostic method for PTDM, however, there is emerging data to support a role for HbA1c beyond 3 months posttransplant.
FPG has low sensitivity during the first year post-transplant. Improved prediction and diagnosis of PTDM may
lead to improvements in patient survival, quality of life and health care costs in future.